JPMorgan Lowers Tempus AI (TEM) PT to $80, Maintains Neutral Rating

Group 1 - Tempus AI, Inc. (NASDAQ:TEM) is recognized as a leading healthcare AI stock, with JPMorgan lowering its price target from $85 to $80 while maintaining a Neutral rating [1][2] - TD Cowen has reiterated a Hold rating on Tempus AI with an unchanged price target of $88, expressing optimism about the company's potential in pharmaceutical research and development efficiency [2][3] - TD Cowen is expanding its coverage on Tempus AI, focusing on the company's data infrastructure and the application of its AI-driven solutions in the healthcare sector [3] Group 2 - Tempus AI specializes in AI-enabled precision medicine, utilizing clinical and molecular data to enhance patient outcomes through machine learning and genomic sequencing [4]